HLA-G variability and haplotypes detected by massively parallel sequencing procedures in the geographicaly distinct population samples of Brazil and Cyprus

Autor(es):Mostrar menos -

Castelli, Erick C. ; Gerasimou, Petroula ; Paz, Michelle A. ; Ramalho, Jaqueline ; Porto, Iane O. P. ; Lima, Thalitta H. A. ; Souza, Andreia S. ; Veiga-Castelli, Luciana C. ; Collares, Cristhianna V. A. ; Donadi, Eduardo A. ; Mendes-Junior, Celso T. ; Costeas, Paul

• Tipo de documento: Artigo Científico
• Fonte: Molecular Immunology; v. 83, p. 115-126, MAR 2017.
• Citações Web of Science: 18

Resumo

The HLA-G molecule presents immunomodulatory properties that might inhibit immune responses when interacting with specific Natural Killer and T cell receptors, such as KIR2DL4, ILT2 and ILT4. Thus, HLA-G might influence the outcome of situations in which fine immune system modulation is required, such as autoimmune diseases, transplants, cancer and pregnancy. The majority of the studies regarding the HLA-G gene variability so far was restricted to a specific gene segment (i.e., promoter, coding or 3' untranslated region), and was performed by using Sanger sequencing and probabilistic models to infer haplotypes. Here we propose a massively parallel sequencing (NGS) with a bioinformatics strategy to evaluate the entire HLA-G regulatory and coding segments, with haplotypes inferred relying more on the straightforward haplotyping capabilities of NGS, and less on probabilistic models. Then, HLA-G variability was surveyed in two admixed population samples of distinct geographical regions and demographic backgrounds, Cyprus and Brazil. Most haplotypes (promoters, coding, 3'UTR and extended ones) were detected both in Brazil and Cyprus and were identical to the ones already described by probabilistic models, indicating that these haplotypes are quite old and may be present worldwide. (C) 2017 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 13/17084-2 - Estudo da variabilidade, controle da expressão e história evolutiva dos genes de Classe I do MHC humano
• Beneficiário: Erick da Cruz Castelli
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/18730-8 - Marcadores imunogenéticos para Diabetes mellitus gestacional
• Beneficiário: Eduardo Antônio Donadi
• Modalidade de apoio: Auxílio à Pesquisa - Regular